194 related articles for article (PubMed ID: 11502816)
1. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment.
Ballarè E; Persani L; Lania AG; Filopanti M; Giammona E; Corbetta S; Mantovani S; Arosio M; Beck-Peccoz P; Faglia G; Spada A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3809-14. PubMed ID: 11502816
[TBL] [Abstract][Full Text] [Related]
2. Genetic abnormalities of somatostatin receptors in pituitary tumors.
Lania A; Mantovani G; Spada A
Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
5. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
[TBL] [Abstract][Full Text] [Related]
7. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
[TBL] [Abstract][Full Text] [Related]
8. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
[TBL] [Abstract][Full Text] [Related]
10. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
Gatto F; Arvigo M; Ferone D
J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
[TBL] [Abstract][Full Text] [Related]
13. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
14. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.
Ferrante E; Pellegrini C; Bondioni S; Peverelli E; Locatelli M; Gelmini P; Luciani P; Peri A; Mantovani G; Bosari S; Beck-Peccoz P; Spada A; Lania A
Endocr Relat Cancer; 2006 Sep; 13(3):955-62. PubMed ID: 16954443
[TBL] [Abstract][Full Text] [Related]
15. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
[TBL] [Abstract][Full Text] [Related]
16. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
17. Resistance to somatostatin (SRIH) analog therapy in acromegaly. Re-evaluation of the correlation between the SRIH receptor status of the pituitary tumor and the in vivo inhibition of GH secretion in response to SRIH analog.
Bertherat J; Chanson P; Dewailly D; Enjalbert A; Jaquet P; Kordon C; Peillon F; Timsit J; Epelbaum J
Horm Res; 1992; 38(1-2):94-9. PubMed ID: 1306525
[TBL] [Abstract][Full Text] [Related]
18. Distribution and functionality of the somatostatin receptor subtypes in acromegaly.
Saveanu A; Gunz G; Dufour H; Enjalbert A; Culler MD; Jaquet P
J Endocrinol Invest; 2003; 26(8 Suppl):4-7. PubMed ID: 15233203
[No Abstract] [Full Text] [Related]
19. Differential effects of somatostatin and angiopeptin on cell proliferation.
Alderton F; Lauder H; Feniuk W; Fan TP; Humphrey PP
Br J Pharmacol; 1998 May; 124(2):323-30. PubMed ID: 9641549
[TBL] [Abstract][Full Text] [Related]
20. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma.
Fougner SL; Borota OC; Berg JP; Hald JK; Ramm-Pettersen J; Bollerslev J
Clin Endocrinol (Oxf); 2008 Mar; 68(3):458-65. PubMed ID: 17941904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]